November 2, 2020 -- TFF Pharmaceuticals and Augmenta Bioworks have agreed to work together to develop COVID-19 monoclonal antibody (mAb) therapies.
The companies will apply TFF Pharmaceuticals' thin-film freezing (TFF) technology to Augmenta's human-derived mAbs as a potential treatment for COVID-19. The technology will be used to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients, according to their agreement.
The companies also agreed to develop formulations suitable for parenteral administration. The TFF dry powder formulas would be reconstituted, potentially mitigating the impacts of cold-chain storage and handling.